NasdaqGM - Nasdaq Real Time Price USD

LeMaitre Vascular, Inc. (LMAT)

Compare
80.09 +1.04 (+1.32%)
At close: June 14 at 4:00 PM EDT
80.09 0.00 (0.00%)
After hours: June 14 at 4:05 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. George W. LeMaitre Chairman & CEO 1.12M 1.31M 1965
Mr. David B. Roberts President & Director 634.85k 1.24M 1964
Mr. Joseph P. Pellegrino Jr. CFO, Secretary & Director 566.19k -- 1965
Mr. Trent G. Kamke Senior Vice President of Operations 445.38k 80.43k 1971
Dr. George D. LeMaitre Founder and Chairman of Scientific Advisory Board 118.48k -- 1934
Ms. Kimberly L. Cieslak Vice President of Marketing -- -- 1973
Mr. Daniel J. Mumford Senior Director of Human Resources -- -- 1982
Mr. Jonathan W. Ngau Senior Vice President of Information Technology -- -- 1974
Mr. Maik D. Helmers Senior Vice President of Sales – Central Europe -- -- 1974
Mr. Ryan H. Connelly Senior Vice President of Advanced Manufacturing Engineering -- -- 1977

LeMaitre Vascular, Inc.

63 Second Avenue
Burlington, MA 01803
United States
781 221 2266 https://www.lemaitre.com
Sector: 
Healthcare
Full Time Employees: 
614

Description

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Corporate Governance

LeMaitre Vascular, Inc.’s ISS Governance QualityScore as of June 1, 2024 is 6. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 7; Compensation: 5.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

July 30, 2024 at 10:59 AM UTC - August 5, 2024 at 12:00 PM UTC

LeMaitre Vascular, Inc. Earnings Date

Recent Events

June 3, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 31, 2024 at 12:00 AM UTC

SD: Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)

May 30, 2024 at 12:00 AM UTC

Dividend Date

May 15, 2024 at 12:00 AM UTC

Ex-Dividend Date

May 10, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

May 2, 2024 at 9:00 PM UTC

Q1 2024 Earnings Call

May 2, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 16, 2024 at 12:00 AM UTC

ARS: Annual Report to Shareholders

February 29, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

February 27, 2024 at 10:00 PM UTC

Q4 2023 Earnings Call

Related Tickers